A study of referral bias in NMOSD and MOGAD cohorts

被引:1
|
作者
Rato, Miguel Leal [1 ,2 ]
Chen, Bo [2 ,3 ]
Francis, Anna [2 ]
Messina, Silvia [2 ]
Miron, Madalina [2 ]
Sharawakanda, Yvonne [2 ]
O'Sullivan, Eoin [4 ]
Cooper, Sarah [5 ]
Fisniku, Leonora [6 ]
Halfpenny, Christopher [7 ]
Martin, Roswell [8 ]
Hobart, Jeremy [9 ]
Rashid, Waqar [10 ]
Hemingway, Cheryl [11 ]
Williams, Victoria [12 ]
Hacohen, Yael [13 ]
Dobson, Ruth [14 ]
Ramdas, Sithara [15 ]
Leite, Maria Isabel [2 ]
Palace, Jacqueline [2 ]
Geraldes, Ruth [2 ]
机构
[1] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Dept Neurociencias & Saude Mental, Serv Neurol, Lisbon, Portugal
[2] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Level 3,West Wing,Headley Way, Oxford OX3 9DU, England
[3] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurol, Wuhan, Peoples R China
[4] Kings Coll Hosp London, Eye Dept, London, England
[5] Univ Hosp Sussex, Worthing, Sussex, England
[6] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England
[7] Univ Hosp Southampton, Southampton, England
[8] Gloucestershire Royal Hosp NHS Trust, Gloucester, England
[9] Plymouth Univ, Peninsula Sch Med & Dent, Plymouth, England
[10] St Georges Univ Hosp NHS Fdn Trust, London, England
[11] Great Ormond St Hosp Sick Children, Dept Neurol, London, England
[12] Guys & St Thomas Nat Hlth Serv Fdn Trust, London, England
[13] UCL, UCL Queen Sq Inst Neurol, Fac Brain Sci, Queen Sq MS Ctr, London, England
[14] Queen Mary Univ London, Wolfson Inst Populat Hlth, Prevent Neurol Unit, London, England
[15] John Radcliffe Hosp, Childrens Hosp, Dept Paediat Neurol, Oxford, England
关键词
NMOSD; MOGAD; Epidemiology; Bias; NEUROMYELITIS-OPTICA; DISEASE;
D O I
10.1016/j.msard.2024.105553
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are rare disorders often seen in highly specialized services or tertiary centres. We aimed to assess if cohort characteristics depend on the origin of the referral catchment areas serviced by our centre (i.e. local, regional or national). Methods: Retrospective cohort study using a national referral service database including local (Oxfordshire), regional (Oxfordshire and neighbouring counties), and national patients. We included patients with the diagnosis of NMOSD, seronegative NMOSD or MOGAD, followed at the Oxford Neuromyelitis Optica Service. Results: We included 720 patients (331 with MOGAD, 333 with aquaporin-4 antibody (AQP4)-NMOSD, and 56 with seronegative NMOSD. The distribution of diagnoses was similar across referral cohorts. There were no significant differences in the proportion of pediatric onset patients, sex, or onset phenotype; more White AQP4NMOSD patients were present in the local than in the national cohort (81 % vs 52 %). Despite no differences in follow-up time, more relapsing MOGAD disease was present in the national than in the local cohort (42.9 % vs. 24 %, p = 0.029). Conclusion: This is the first study assessing the impact of potential referral bias in cohorts of NMOSD or MOGAD. The racial difference in the AQP4-NMOSD cohorts likely reflects the variation in the population demographics rather than a referral bias. The over representation of relapsing MOGAD patients in the national cohort probably is a true referral bias and highlights the need to analyze incident cohorts when describing disease course and prognosis. It seems reasonable therefore to compare MOGAD and NMOSD patients seen withing specialised centres to general neurology services, provided both use similar antibody assays.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] symptomatic Lesions in MOGAD and NMOSD
    Yuen, N.
    Perrier, R. L.
    Casserly, C. S.
    Morrow, S. A.
    Racosta, J. M.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 161 - 161
  • [2] Is there truly no progression in NMOSD and MOGAD?
    Lechner-Scott, J.
    Giovannoni, G.
    Ch, Hawkes
    Levy, M.
    Ea, Yeh
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2025, 94
  • [3] Emerging therapies for MOGAD/NMOSD
    Burton, Jodie
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [4] Volumetric Differences in MOGAD and NMOSD
    Rechtman, Ariel
    Zveik, Omri
    Haham, Nitzan
    Brill, Livnat
    Dembinsky, Adi Vaknin
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 538 - 538
  • [5] Treatment of NMOSD and MOGAD: An Update
    Bennett, Jeffrey L.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 123 - 124
  • [6] Rheumatological comorbidities and autoantibodies in NMOSD and MOGAD
    Barreras, P.
    Vasileiou, E. S.
    Sotirchos, E. S.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 755 - 755
  • [7] Diagnosis and clinical features of NMOSD and MOGAD
    Kim, Ho Jin
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 123 - 123
  • [8] What's new in NMOSD and MOGAD?
    Marignier, R.
    REVUE NEUROLOGIQUE, 2024, 180 (09) : 957 - 962
  • [9] NMOSD and MOGAD: an evolving disease spectrum
    Uzawa, Akiyuki
    Oertel, Frederike Cosima
    Mori, Masahiro
    Paul, Friedemann
    Kuwabara, Satoshi
    NATURE REVIEWS NEUROLOGY, 2024, 20 (10) : 602 - 619
  • [10] COVID-19 infections in NMOSD and MOGAD: a population based study
    Capobianco, M.
    Comi, G.
    Sormani, M. P.
    Patti, F.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 92 - 92